MedVi

About MedVi

Medvi is one of the more established players in the GLP-1 telehealth space, having launched in 2021 before the current wave of competitors entered the market. The company offers both brand-name medications (including Ozempic and Wegovy) and compounded semaglutide, with pricing spanning a wide range from 9 to ,150 per month. This breadth of options means Medvi can serve patients across the affordability spectrum, from those seeking budget compounded formulations to those who prefer FDA-approved brand products.

The availability of brand-name GLP-1 medications is a meaningful differentiator. Many telehealth providers offer only compounded versions, which, while more affordable, lack the regulatory oversight and consistency guarantees of FDA-approved drugs. Patients who want the assurance of a brand-name product prescribed through a telehealth channel will find Medvi to be one of relatively few options. The company also provides quick access to prescriptions, with many patients reporting same-day or next-day consultations.

Medvi’s Trustpilot profile shows a 4.4-star rating across an impressive 11,850+ reviews. At this volume, the rating carries substantial statistical reliability. Patients frequently highlight the speed of the process and the range of available medications. Negative reviews tend to focus on pricing clarity, particularly around the significant cost difference between compounded and brand-name options, and on limited post-prescription engagement from providers.

Despite the strong Trustpilot numbers, Medvi carries an F rating with the Better Business Bureau, which indicates a meaningful volume of unresolved complaints. This disconnect between high patient satisfaction on Trustpilot and poor BBB standing is not uncommon in telehealth but warrants attention. The BBB complaints often center on billing disputes and subscription management issues. Ongoing clinical support is limited, with no integrated lab monitoring or dietitian access in standard plans.

Medvi’s longevity and scale give it operational credibility that newer entrants lack. The company has been filling GLP-1 prescriptions longer than most competitors and has processed a high volume of patients. For our editorial team, the combination of brand-name access, high review volume, and early market entry creates a solid foundation, even as the BBB rating and support gaps prevent a top-tier score.

At a Glance